PWW
REGN icon

Pettyjohn Wood & White’s Regeneron Pharmaceuticals REGN Stock Holding History

Pettyjohn Wood & White’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-535
Closed -$316K – 168
2022
Q2 		$316K Buy
+535
New +$348K 0.07% 137

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pettyjohn Wood & White's REGN Position: Q3 2022 in Review

Pettyjohn Wood & White sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 535 shares — an estimated $316K sold.

Pettyjohn Wood & White first reported a position in REGN in Q2 2022 and held it in 1 quarter. The position peaked at $316K in Q2 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Pettyjohn Wood & White reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Pettyjohn Wood & White sold 535 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $316K.
  • Pettyjohn Wood & White first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Pettyjohn Wood & White's Regeneron Pharmaceuticals position peaked at $316K in Q2 2022.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Pettyjohn Wood & White's 13F filing for Q3 2022, filed 28 Oct 2022.